SynthesisResearch and practice in thrombosis and haemostasis2026
Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.
Synthesis in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For women with antiphospholipid syndrome (APS) and placenta-mediated complications, the efficacy of heparin during subsequent pregnancies is uncertain. Objectives: This study systematically reviewed high-quality evidence on efficacy of low-molecular-weight heparin (LMWH) to prevent recurrent placenta-mediated pregnancy complications in women with APS. Methods: We searched Embase, MEDLINE, and CENTRAL to identify randomized controlled trials (RCTs) that assessed use of LMWH compared with any control in pregnant women with APS and previous placenta-mediated pregnancy complications (intrauterine growth restriction; birth of a small for gestational infant; preeclampsia; hemolysis, elevated liver enzymes, and low platelets syndrome; late fetal loss; and placental abruption). The primary outcome was recurrence of placenta-mediated pregnancy complications. Results: We identified 4007 records and included 2 RCTs. The TIPPS trial randomized eligible women to dalteparin or no dalteparin; 21 women with APS were included in this systematic review. The FRUIT trial randomized 32 women with APS to dalteparin and aspirin or aspirin only. The primary outcome of this systematic review occurred in 4 of 16 women in the intervention group of the FRUIT trial and in 3 to 6 of 16 women in the control group (risk difference, 6.25%; 95% CI, -22.3% to 34.8%; ranging to -12.5%; 95% CI, -44.3% to 19.3%, due to absent reporting on coinciding complications). The trials did not report on the outcome and population as defined in the current review in a manner that allowed pooling the primary outcome. Conclusion: There is no high-quality evidence from RCTs that demonstrates a beneficial effect of LMWH in women with APS and placenta-mediated pregnancy complications without a history of recurrent miscarriage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.